Sai Parenterals Limited renews AUD 30 million OTC supply agreement with Australian pharmacy chain, expanding product portfolio and agreement tenure.
NGL Fine-Chem Limited (NGLFINE) reports Q1FY27 results with sustained demand, profitability growth, and strategic capex plans.
Rubicon Research Limited (RUBICON) stock moves up 10% intraday, breaking out above its 6-month resistance trendline at ₹1646.
Rubicon Research Limited (NSE: RUBICON) stock breaks out, moving up 6% intraday to ₹1723.7, clearing its 6M resistance trendline.
Marksans Pharma Limited (MARKSANS) stock clears its 6M resistance trendline, gaining 5% intraday. This breakout move is backed by Q1fy27 profitability at all.
Marksans Pharma Limited (MARKSANS) stock breaks out with an 11% intraday gain, clearing its 6M resistance trendline.
Marksans Pharma Limited (MARKSANS) reports record Q1FY27 results with EBITDA up 113% YoY, PAT up 174% and highest-ever revenue in UK & Europe.
Marksans Pharma Limited (MARKSANS) stock price gains 8% intraday, breaks out from its 6-month resistance trendline. Current price at ₹303.85.
Kopran Limited (NSE: KOPRAN) Q1 FY 2026-27 results: financial highlights, operational performance, and strategic outlook.
Sanofi India Limited (SANOFI) announces changes in its Risk Management Committee, including the stepping down of Mr. Rachid Ayari.